Format
Sort by

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 201

1.

La différenciation sexuelle; facteur déterminant des formes de l'obésité.

VAGUE J.

Presse Med. 1947 May 24;55(30):339. Undetermined Language. No abstract available.

PMID:
18918084
2.

Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity.

Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP, Wagner JA, Wu M, Knopps A, Xiang AH, Utzschneider KM, Kahn SE, Olefsky JM, Buchanan TA, Scherer PE.

J Biol Chem. 2004 Mar 26;279(13):12152-62.

3.

Muscle-specific Pparg deletion causes insulin resistance.

Hevener AL, He W, Barak Y, Le J, Bandyopadhyay G, Olson P, Wilkes J, Evans RM, Olefsky J.

Nat Med. 2003 Dec;9(12):1491-7.

PMID:
14625542
4.

The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus.

RANDLE PJ, GARLAND PB, HALES CN, NEWSHOLME EA.

Lancet. 1963 Apr 13;1(7285):785-9. No abstract available.

PMID:
13990765
5.
6.

The metabolic syndrome: peroxisome proliferator-activated receptor gamma and its therapeutic modulation.

Gurnell M, Savage DB, Chatterjee VK, O'Rahilly S.

J Clin Endocrinol Metab. 2003 Jun;88(6):2412-21. Review.

PMID:
12788836
7.

Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma.

Savage DB, Tan GD, Acerini CL, Jebb SA, Agostini M, Gurnell M, Williams RL, Umpleby AM, Thomas EL, Bell JD, Dixon AK, Dunne F, Boiani R, Cinti S, Vidal-Puig A, Karpe F, Chatterjee VK, O'Rahilly S.

Diabetes. 2003 Apr;52(4):910-7.

8.
9.

Insulin resistance in type 2 diabetes: association with truncal obesity, impaired fitness, and atypical malonyl coenzyme A regulation.

Båvenholm PN, Kuhl J, Pigon J, Saha AK, Ruderman NB, Efendic S.

J Clin Endocrinol Metab. 2003 Jan;88(1):82-7. Erratum in: J Clin Endocrinol Metab. 2003 May;88(5):2036.

PMID:
12519834
10.

Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity.

Pajvani UB, Du X, Combs TP, Berg AH, Rajala MW, Schulthess T, Engel J, Brownlee M, Scherer PE.

J Biol Chem. 2003 Mar 14;278(11):9073-85.

11.

Malonyl coenzyme A and the regulation of functional carnitine palmitoyltransferase-1 activity and fat oxidation in human skeletal muscle.

Rasmussen BB, Holmbäck UC, Volpi E, Morio-Liondore B, Paddon-Jones D, Wolfe RR.

J Clin Invest. 2002 Dec;110(11):1687-93.

12.

Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation.

Tomas E, Tsao TS, Saha AK, Murrey HE, Zhang Cc Cc, Itani SI, Lodish HF, Ruderman NB.

Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16309-13.

13.

A central role for JNK in obesity and insulin resistance.

Hirosumi J, Tuncman G, Chang L, Görgün CZ, Uysal KT, Maeda K, Karin M, Hotamisligil GS.

Nature. 2002 Nov 21;420(6913):333-6.

PMID:
12447443
14.

Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study.

Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA.

Am J Epidemiol. 2002 Dec 1;156(11):1070-7.

PMID:
12446265
15.

Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis.

Yamauchi T, Kamon J, Waki H, Imai Y, Shimozawa N, Hioki K, Uchida S, Ito Y, Takakuwa K, Matsui J, Takata M, Eto K, Terauchi Y, Komeda K, Tsunoda M, Murakami K, Ohnishi Y, Naitoh T, Yamamura K, Ueyama Y, Froguel P, Kimura S, Nagai R, Kadowaki T.

J Biol Chem. 2003 Jan 24;278(4):2461-8.

16.

Profiling gene transcription in vivo reveals adipose tissue as an immediate target of tumor necrosis factor-alpha: implications for insulin resistance.

Ruan H, Miles PD, Ladd CM, Ross K, Golub TR, Olefsky JM, Lodish HF.

Diabetes. 2002 Nov;51(11):3176-88. Erratum in: Diabetes. 2002 Feb;52(2):578.

17.

Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase.

Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T.

Nat Med. 2002 Nov;8(11):1288-95.

PMID:
12368907
18.

Effects of insulin treatment in type 2 diabetic patients on intracellular lipid content in liver and skeletal muscle.

Anderwald C, Bernroider E, Krssak M, Stingl H, Brehm A, Bischof MG, Nowotny P, Roden M, Waldhäusl W.

Diabetes. 2002 Oct;51(10):3025-32.

19.

The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects.

Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M, Olefsky JM.

Diabetes. 2002 Oct;51(10):2968-74.

20.

Adipose tissue as a buffer for daily lipid flux.

Frayn KN.

Diabetologia. 2002 Sep;45(9):1201-10. Review.

PMID:
12242452
Items per page

Supplemental Content

Support Center